Hemos leído sobre ... Tratamientos

Última actualización: 3 junio 2024
MAYO 2024
  • Solignac M, Cabrera N, Fouillet-Desjonqueres M, Duquesne A, Laurent A, Foray AP, et al.
    JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.
    J Autoimmun. 2024 May 25;147:103248. doi: 10.1016/j.jaut.2024.103248.

  • Ishikawa T, Nishimura K, Okamoto N, Akamine K, Inoue N, Irabu H, et al.
    Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: a systematic review.
    Mod Rheumatol. 2024 May 25:roae050. doi: 10.1093/mr/roae050.

  • van Dijk BT, Bergstra SA, van den Berg JM, Schonenberg-Meinema D, van Suijlekom-Smit LWA, van Rossum MAJ, et al.
    Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
    Pediatr Rheumatol Online J. 2024 May 10;22(1):53. doi: 10.1186/s12969-024-00989-x.

  • Möhlmann JE, de Roock S, Egas AC, Weijden ET, Doeleman MJH, Huitema ADR, et al
    Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay.
    Pediatr Rheumatol Online J. 2024 May 7;22(1):52. doi: 10.1186/s12969-024-00988-y.

ABRIL 2024
  • Brossard P, Laveille C.
    Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.
    Rheumatol Ther. 2024 Apr 25. doi: 10.1007/s40744-024-00669-y. Online ahead of print.

MARZO 2024
  • Zajc Avramovič M, Toplak N, Markelj G, Emeršič N, Avčin T
    Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection.
    Arthritis Res Ther. 2024 Mar 14;26(1):69. doi: 10.1186/s13075-024-03303-y.

  • Belbézier A, Nguyen TTT, Arnaud M, Ducotterd B, Vangout M, Deroux A, et al.
    Treatment of non-systemic Sjogren's syndrome: Potential prevention of systematization with immunosuppressant agent/biotherapy.
    J Transl Autoimmun. 2024 Mar 3;8:100238. doi: 10.1016/j.jtauto.2024.100238.

  • Glatre A, Pascard M, Hentzien M, Salmon JH, Servettaz A, Robbins A.
    Eosinopenia and routine inflammatory biomarkers are helpful for the diagnosis of infection in patients treated with IL-6 pathway antagonists.
    RMD Open. 2024 Feb 9;10(1):e003998. doi: 10.1136/rmdopen-2023-003998.

  • Kim H.
    Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.
    Expert Rev Clin Immunol. 2024 Feb 1:1-14. doi: 10.1080/1744666X.2024.2312819.

ENERO 2024
  • Vojinović J, Foeldvari I, Dehoorne J, Panaviene V, Susic G, Horneff G, et al.
    Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2024 Jan 4;63(1):140-148. doi: 10.1093/rheumatology/kead183.

  • Lovell DJ, Tzaribachev N, Henrickson M, Simonini G, Griffin TA, Alexeeva E, et al.
    Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.
    Rheumatology (Oxford). 2024 Jan 18:keae025. doi: 10.1093/rheumatology/keae025. Epub ahead of print.

  • Simonds MM, Freer ST, Brescia AMC.
    Methotrexate inhibits BMP4 and abrogates the hypertrophic chondrocyte phenotype of synovial fibroblasts in juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2024 Jan 2;22(1):6. doi: 10.1186/s12969-023-00940-6.

  • Erkens RGA, Calis JJA, Verwoerd A, De Roock S, Ter Haar NM, Den Engelsman G, et al.
    Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN
    Arthritis Rheumatol. 2024 Jan;76(1):119-129. doi: 10.1002/art.42656.

  • Welzel T, Golhen K, Atkinson A, Gotta V, Ternant D, Kuemmerle-Deschner JB, Michler C, Koch G, van den Anker JN, Pfister M, Woerner A.
    Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases.
    Pediatr Rheumatol Online J. 2024 Jan 2;22(1):5. doi: 10.1186/s12969-023-00930-8.

  • Ma L, Peng L, Zhao J, Bai W, Jiang N, Zhang S, et al.
    Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.
    Autoimmun Rev. 2023 Dec;22(12):103440. doi: 10.1016/j.autrev.2023.103440.

  • Agarwal A, Diaz A, Al-Dehneem R, Pineda RM, Khattri S.
    Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.
    J Drugs Dermatol. 2023 Dec 1;22(12):1183-1190. doi: 10.36849/JDD.7500.

  • Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, et al.
    Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
    Arthritis Rheumatol. 2023 Dec;75(12):2185-2194. doi: 10.1002/art.42652.

  • Taubmann J, Müller F, Yalcin Mutlu M, Völkl S, Aigner M, Bozec A, et al.
    CD19 CAR-T cell treatment: Unraveling the role of B cells in Systemic Lupus Erythematosus.
    Arthritis Rheumatol. 2023 Dec 19. doi: 10.1002/art.42784. Epub ahead of print.

  • Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, et al.
    Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
    Ann Rheum Dis. 2023 Dec 21:ard-2023-224854. doi: 10.1136/ard-2023-224854. Epub ahead of print.

  • Nepal D, Gazeley D.
    Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus.
    Rheumatology (Oxford). 2023 Dec 1;62(12):3804-3810. doi: 10.1093/rheumatology/kead416.

  • Coşkuner T, Çağlayan Ş, Akgün Ö, Torun R, Yayla ENS, Bagrul IL, Kılbaş G, Yener GO, Köse H, Öztürk K, Baba Ö, Çakan M, Demir F, Sönmez HE, Kalyoncu M, Kılıç SN, Yüksel S, Bağlan E, Bakkaloğlu SA, Ünsal E, Aktay Ayaz N, Sözeri B.
    The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study.
    Expert Opin Biol Ther. 2023 Nov 16. doi: 10.1080/14712598.2023.2282133.

  • Martins FR, Azevedo AC, Ganhão S, Aguiar F, Rodrigues M, Brito I.
    Anakinra and hepatotoxicity in pediatric rheumatology: a case series.
    Pediatr Rheumatol Online J. 2023 Oct 6;21(1):112. doi: 10.1186/s12969-023-00891-y.

  • Berrueco R, González-Forster E, Deya-Martinez A, Solsona M, García-García A, Calzada-Hernández J, Yiyi L, Vlagea A, Ruiz-Llobet A, Alsina L.
    Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity.
    Front Pediatr. 2023 Oct 17;11:1174671. doi: 10.3389/fped.2023.1174671. eCollection 2023.

  • Bagri NK, Chew C, Ramanan AV.
    Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward.
    Paediatr Drugs. 2023 Sep 29. doi: 10.1007/s40272-023-00594-7. 

  • Schett G, Mackensen A, Mougiakakos D.
    CAR T-cell therapy in autoimmune diseases.
    Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126-1. Online ahead of print.

  • Vermeer E, Hebing RCF, van de Meeberg MM, Lin M, de Meij TGJ, Struys EA, et al.
    Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature.
    Curr Rheumatol Rep. 2023 Sep 28. doi: 10.1007/s11926-023-01116-7. Online ahead of print.

  • Perrin T, Coutier L, Ranchoup J, Rifard A, Eymery M, Ohlmann C, et al.
    Methotrexate does not affect lung function in children with juvenile idiopathic arthritis.
    Pediatr Pulmonol. 2023 Sep 13. doi: 10.1002/ppul.26681. Online ahead of print.

  • Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š, Antón J, Wang Z, Meszaros G, Araújo J, Liao R, Keller S, Brunner HI, Ruperto N; JUVE-BASIS investigators; Paediatric Rheumatology International Trials Organisation.
    Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Lancet. 2023 Aug 12;402(10401):555-570. doi: 10.1016/S0140-6736(23)00921-2. Epub 2023 Jul 6. Erratum in: Lancet. 2023 Aug 12;402(10401):528.

  • Rife EC, Cron RQ.
    Janus kinase inhibition in juvenile idiopathic arthritis.
    Lancet. 2023 Aug 12;402(10401):508-509. doi: 10.1016/S0140-6736(23)01134-0. Epub 2023 Jul 6.

JULIO 2023
  • van Til JA, Kip MMA, Schatorjé EJH, Currie G, Twilt M, Benseler SM et al.
    Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
    Pediatr Rheumatol Online J. 2023 Jul 11;21(1):69. doi: 10.1186/s12969-023-00845-4.

  • Melki I, Frémond ML.
    JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases.
    J Clin Med. 2023 Jul 14;12(14):4695. doi: 10.3390/jcm12144695.

  • Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š et al.
    Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Lancet. 2023 Aug 12;402(10401):555-570. doi: 10.1016/S0140-6736(23)00921-2. Epub 2023 Jul 6. Erratum in: Lancet. 2023 Aug 12;402(10401):528.

  • Ruperto N, Lovell DJ, Berman A, Anton J, Viola DO, Lauwerys B et al.
    Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.
    J Rheumatol. 2023 Jul 15:jrheum.2022-1320. doi: 10.3899/jrheum.2022-1320. Epub ahead of print.

  • Myachikova VY, Maslyanskiy AL, Moiseeva OM, Vinogradova OV, Gleykina EV, Lavrovsky Y et al.
    Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.
    J Am Coll Cardiol. 2023 Jul 4;82(1):30-40. doi: 10.1016/j.jacc.2023.04.046.

MAYO 2023
  • Maniscalco V, Maccora I, Girodo F, Tomaselli M, Priolo G, Marrani E, et al.
    Anti-IL17 treatment in childhood chronic rheumatic diseases.
    Expert Opin Biol Ther. 2023 May 19:1-13. doi: 10.1080/14712598.2023.2215923. Epub ahead of print.

  • Manatpreeprem R, Lerkvaleekul B, Vilaiyuk S.
    Factors associated with medication adherence among children with rheumatic diseases.
    Front Pharmacol. 2023 May 5;14:1149320. doi: 10.3389/fphar.2023.1149320.

  • Currie GR, Groothuis-Oudshoorn CGM, Twilt M, Kip MMA, IJzerman MJ, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung R, Marshall DA.
    What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey.
    Clin Rheumatol. 2023 May 19. doi: 10.1007/s10067-023-06616-6. Epub ahead of print.

  • Correll CK, Stryker S, Collier D, Phillips TA, Dennos AC, Balevic SJ, Beukelman T; CARRA Registry Investigators.
    Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry.
    RMD Open. 2023 May;9(2):e002943. doi: 10.1136/rmdopen-2022-002943.

MARZO 2023
  • Sukharomana M, Charuvanij S.
    Outcomes of intraarticular triamcinolone acetonide injection in children with non-systemic juvenile idiopathic arthritis.
    Clin Rheumatol. 2023 Mar 9. doi: 10.1007/s10067-023-06569-w. Online ahead of print.

  • Atzeni F, Gozza F, Riva A, Alciati A, Galloway J.
    Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus.
    Expert Opin Pharmacother. 2023 Mar 28:1-11. doi: 10.1080/14656566.2023.2195050. Online ahead of print.

  • Maccora I, Oliverio T, Pagnini I, Marrani E, Mastrolia MV, Simonini G.
    Baricitinib for juvenile idiopathic arthritis: a monocentric case series
    Ann Rheum Dis. 2023 Feb 8:ard-2022-223815. doi: 10.1136/ard-2022-223815. 

  • Martini G, Meneghel A, Fastiggi M, Dell'Apa F, Vittadello F, Zulian F.
    Strategic use of levofolinic acid for methotrexate-induced side effects in juvenile idiopathic arthritis: a prospective observational study.
    Pediatr Rheumatol Online J. 2023 Feb 15;21(1):18. doi: 10.1186/s12969-023-00800-3.

  • Horneff G, Minden K, Rolland C, Daly ACH, Borlenghi C, Ruperto N.
    Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review.
    Pediatr Rheumatol Online J. 2023 Feb 24;21(1):20. doi: 10.1186/s12969-023-00798-8.

  • Weiss PF, Sears CE, Brandon TG, Forrest CB, Neu E, Kohlheim M, Leal J, Xiao R, Lovell D.
    Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial.
    Trials. 2023 Feb 8;24(1):100. doi: 10.1186/s13063-022-07038-6.

ENERO 2023
  • Benucci M, Bernardini P, Coccia C, De Luca R, Levani J, Economou A, et al.
    JAK inhibitors and autoimmune rheumatic diseases.
    Autoimmun Rev. 2023 Jan 14;22(4):103276. doi: 10.1016/j.autrev.2023.103276. Epub ahead of print.

  • Giani T, Luppino AF, Ferrara G.
    Treatment Options in Pediatric Behçet's Disease.
    Paediatr Drugs. 2023 Jan 10:1–27. doi: 10.1007/s40272-022-00548-5. Epub ahead of print.

  • Vollbach K, Tenbrock K, Wagner N, Horneff G, Klein A, Foeldvari I, Haas JP, Aries P, Gauler G, Striesow F, Hoff P, Scholz C, Tatsis S, Seipelt E, Klotsche J, Minden K.
    Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO
    Arthritis Res Ther. 2022 Dec 13;24(1):271. doi: 10.1186/s13075-022-02968-7.

  • Hahn T, Daymont C, Beukelman T, Groh B, Hays K, Bingham CA, Scalzi L; CARRA Registry investigators.
    Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Pediatr Rheumatol Online J. 2022 Nov 25;20(1):107. doi:10.1186/s12969-022-00770-y.

  • Broekaert IJ, Klein A, Windschall D, Rogalski B, Weller-Heinemann F, Oommen P, et al.
    Development of Inflammatory Bowel Disease in Children with Juvenile Idiopathic Arthritis Treated with Biologics.
    J Pediatr Gastroenterol Nutr. 2022 Nov 17. doi: 10.1097/MPG.0000000000003656. Online ahead of print.

  • Montag LJ, Horneff G, Hoff P, Klein A, Kallinich T, Foeldvari I, Seipelt E, Tatsis S, Peer Aries MD, Niewerth M, Klotsche J, Minden K.
    Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study.
    RMD Open. 2022 Oct;8(2):e002520. doi: 10.1136/rmdopen-2022-002520.PMID: 36283758

  • Thiele F, Klein A, Klotsche J, Windschall D, Dressler F, Kuemmerle-Deschner J, Minden K, Foeldvari I, Foell D, Mrusek S, Oommen PT, Horneff G.
    Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.
    Rheumatology (Oxford). 2022 Oct 12:keac587. doi: 10.1093/rheumatology/keac587. Online ahead of print.

  • Del Giudice E, Sota J, Orlando F, Picciano L, Cimaz R, Cantarini L, Mauro A
    Off-label use of canakinumab in pediatric rheumatology and rare diseases.
    Front Med (Lausanne). 2022 Oct 18;9:998281. doi: 10.3389/fmed.2022.998281. eCollection 2022.

  • Brogan P, Naden R, Ardoin SP, Cooper JC, De Benedetti F, Dicaire JF, et al.
    The pediatric glucocorticoid toxicity index
    Semin Arthritis Rheum. 2022 Oct;56:152068. doi: 10.1016/j.semarthrit.2022.152068. Epub 2022 Jul 14.

  • Alehashemi S, Dasari S, de Jesus AA, Cowen EW, Lee CR, Goldbach-Mansky R, McPhail ED.
    Anakinra-Associated Amyloidosis.
    JAMA Dermatol. 2022 Oct 12. doi: 10.1001/jamadermatol.2022.2124. Online ahead of print.PMID: 36223107

  • Aydın F, Çakar N, Kurt T, Çelikel Acar B, Çelikel E, Özçakar ZB, Yalçınkaya F.
    What are the factors associated with the duration of remission of intra-articular corticosteroid injection in juvenile idiopathic arthritis?
    Clin Rheumatol. 2022 Aug 11. doi: 10.1007/s10067-022-06327-4. 

  • Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes IB, et al.
    Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
    Ann Rheum Dis. 2022 Aug 11:annrheumdis-2022-222784. doi: 10.1136/ard-2022-222784. Online ahead of print.

  • Niinomi I, Oyama S, Inada A, Wakabayashi T, Hirai T, Kambara H, Iida T, Uchida M, Sano Y, Hosohata K.
    Adverse event profiles of drugs used for treatment of juvenile idiopathic arthritis according to spontaneous reporting system database
    Int J Clin Pharmacol Ther. 2022 Aug 4. doi: 10.5414/CP204255. 

JULIO 2022
  • Kostik MM, Isupova EA, Belozerov K, Likhacheva TS, Suspitsin EN, Raupov R, Masalova VV, Chikova IA, Dubko MF, Kalashnikova OV, Chasnyk VG, Cron RQ.
    Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.
    Front Pediatr. 2022 Jul 28;10:894846. doi: 10.3389/fped.2022.894846.

  • Arnold DD, Yalamanoglu A, Boyman O.
    Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
    Front Immunol. 2022 Jul 6;13:888392. doi: 10.3389/fimmu.2022.888392.

  • Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, Keefe D, Papanastasiou P, Bao W, Forrer P, Patekar M.
    Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
    Paediatr Drugs. 2022 Jul;24(4):377-387. doi: 10.1007/s40272-022-00507-0.

JUNIO 2022
  • Cáceres VA, Piñeiro ML, Ibáñez-Beróiz B, Enguita-Germán M.
    Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic.
    J Clin Rheumatol. 2022 Jun 3. doi: 10.1097/RHU.0000000000001862. Online ahead of print.

MAYO 2022
  • Wang J, Zhang X, Geng X, Shi J, Jia X, Dang S, Wang W.
    Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases.
    EClinicalMedicine. 2022 May 5;48:101425. doi: 10.1016/j.eclinm.2022.101425

  • Sener S, Basaran O, Bilginer Y, Kiper N, Ozen S.
    Bradypnea in a child taking tumor necrosis factor-alpha inhibitors.
    Pediatr Pulmonol. 2022 May 23. doi: 10.1002/ppul.25985. Epub ahead of print. PMID: 35604108.

ABRIL 2022
  • Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Marshall DA.
    Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study.
    Pediatr Rheumatol Online J. 2022 Apr 11;20(1):25. doi: 10.1186/s12969-022-00682-x.

MARZO 2022
  • Chun A, Muhammad LN, De Ranieri D.
    Comparison of efficacy between triamcinolone acetonide and triamcinolone hexacetonide for intraarticular therapy in juvenile idiopathic arthritis: a retrospective analysis.
    BMC Rheumatol. 2022 Mar 31;6(1):18. doi: 10.1186/s41927-022-00249-z.

  • Chean CS, Raval P, Ogollah RO, Hall A, Roddy E, Foster NE.
    Accuracy of placement of ultrasound-guided corticosteroid injection for subacromial pain (impingement) syndrome does not influence pain and function: Secondary analysis of a randomised controlled trial.
    Musculoskeletal Care. 2022 Mar 22. doi: 10.1002/msc.1634. Online ahead of print.

  • Fingerhutová Š, Jančová E, Doležalová P.
    Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
    Front Pediatr. 2022 Mar 7;10:823847. doi: 10.3389/fped.2022.823847

  • Osswald D, Rameau AC, Terzic J, Sordet C, Bourcier T, Sauer A.
    Risk Factors Leading to Anti-TNF Alpha Therapies in Pediatric Severe Uveitis.
    Front Pediatr. 2022 Mar 4;10:802977. doi: 10.3389/fped.2022.802977.

  • Kostik MM, Raupov RK, Suspitsin EN, Isupova EA, Gaidar EV, Gabrusskaya TV, Kaneva MA, Snegireva LS, Likhacheva TS, Miulkidzhan RS, Kosmin AV, Tumakova AV, Masalova VV, Dubko MF, Kalashnikova OV, Aksentijevich I, Chasnyk VG.
    The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
    Front Pediatr. 2022 Feb 8;10:820586. doi: 10.3389/fped.2022.820586.

  • Zic C.
    Considerations for the Primary Care Provider Caring for Patients with Juvenile Idiopathic Arthritis Receiving Biologic Therapy.
    Pediatr Ann. 2022 Feb;51(2):e54-e56. doi: 10.3928/19382359-20220118-02. Epub 2022 Feb 1.

ENERO 2022
  • Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S.
    Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
    Nat Rev Rheumatol. 2022 Jan 5:1–13. doi: 10.1038/s41584-021-00726-8.

  • Rubin S, Ohana O, Goldberg O, Peled O, Gendler Y, Habot-Wilner Z, Levinsky Y, Tal R, Harel L, Amarilyo G.
    The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2022 Jan 29;20(1):5. doi: 10.1186/s12969-022-00666-x.

  • Jurgen Sota, Stefano Gentileschi, Maria Orsetta Perfetti, Bruno Frediani, Gian Marco Tosi, Luca Cantarini, Claudia Fabiani.
    Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet's Syndrome.
    Ophthalmol Ther. 2021 Dec;10(4):1129-1135. doi: 10.1007/s40123-021-00387-6.

  • Jurgen Sota, Donato Rigante, Rolando Cimaz, Marco Cattalini, Micol Frassi et al.
    Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry.
    Rheumatology (Oxford). 2021 Dec 1;60(12):5705-5712. doi: 10.1093/rheumatology/keab419.

  •  Christopher J Failing, Kevin F Boehnke, Meredith Riebschleger.
    Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2021 Dec 13;19(1):171. doi: 10.1186/s12969-021-00656-5.

  • Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG et al.
    Colchicine in Cardiovascular Disease: In-Depth Review.
    Circulation. 2022 Jan 4;145(1):61-78. doi: 10.1161/CIRCULATIONAHA.121.056171. Epub 2021 Dec 29.

  • Failing CJ, Boehnke KF, Riebschleger M.
    Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2021 Dec 13;19(1):171. doi: 10.1186/s12969-021-00656-5.

  • Demirkan FG, Ulu K, Öztürk K, Karadağ ŞG, Özdel S, Sönmez HE, Çakmak F, Demir F, Sözeri B, Aktay Ayaz N.
    Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group.
    Expert Opin Biol Ther. 2021 Nov 16:1-6. doi: 10.1080/14712598.2021.2002296. Online ahead of print.

  • Yue X, Huang B, Hincapie AL, Wigle PR, Li Y, Qiu T, Lovell DJ, Morgan EM, Guo JJ.
    Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA.
    Rheumatology (Oxford). 2021 Sep 1;60(9):4063-4073. doi: 10.1093/rheumatology/keaa877.

  • Jaime-Pérez JC, González-Treviño M, Meléndez-Flores JD, Ramos-Dávila EM, Cantú-Rodriguez OG, Gutiérrez-Aguirre CH, Galarza-Delgado DA, Gómez-Almaguer D.
    Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort.
    Clin Rheumatol. 2021 Sep 29. doi: 10.1007/s10067-021-05931-0. Online ahead of print.

  • Thiele F, Klein A, Hospach A, Windschall D, Mrusek S, Ruehlmann JM, Horneff G.
    Efficacy and Safety of Etanercept Biosimilars Compared with the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study.
    ACR Open Rheumatol. 2021 Aug 27. doi: 10.1002/acr2.11325. Online ahead of print.

  •  Sota J, Gentileschi S, Perfetti MO, Frediani B, Tosi GM, Cantarini L, Fabiani C.
    Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behcet's Syndrome.
    Ophthalmol Ther. 2021 Aug 30. doi: 10.1007/s40123-021-00387-6. Online ahead of print.

JULIO 2021
  • Ong MS, Rothman D, Barmettler S, Son MB, Lo M, Roberts J, Natter M.
    New-onset Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Childhood-onset Rheumatic Diseases.
    Rheumatology (Oxford). 2021 Jul 30:keab626. doi: 10.1093/rheumatology/keab626. Epub ahead of print. PMID: 34329428.

  • Maccora I, Lombardi N, Crescioli G, Bettiol A, Bonaiuti R, Pagnini I, Maniscalco V, Marrani E, Mastrolia MV, Ravaldi C, Consolini R, Cattalini M, Vannacci A, Simonini G.
    OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2021 Jul 17:keab572. doi: 10.1093/rheumatology/keab572. Epub ahead of print. PMID: 34273158.

  •  Ruperto N, Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Cimaz R, Dare J, Espada G, Faugier E, Ferrandiz M, Gerloni V, Quartier P, Silva CA, Wagner-Weiner L, Gandhi Y, Passarell J, Nys M, Wong R, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO).
    Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis.
    J Rheumatol. 2021 Jul;48(7):1073-1081. doi: 10.3899/jrheum.200154. Epub 2021 Jan 15. PMID: 33452173.

  • Waldron JL, Schworer SA, Kwan M.
    Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. Clin Rev
    Allergy Immunol. 2021 Jul 28. doi: 10.1007/s12016-021-08879-w. Online ahead of print

JUNIO 2021
  • Colleen K Correll, Peter Shrader, Anne Dennos, Thomas Phillips, Natalie J Shiff, Ruud H J Verstegen, Timothy Beukelman, CARRA Registry Investigators.
    Effectiveness and Safety of High-Dose Biologics in Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance.
    Arthritis Care Res (Hoboken). 2021 Jun 13. doi: 10.1002/acr.24727. Online ahead of print.

  • Jean Baer, Jens Klotsche, Ivan Foeldvari.
    Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index.
    Clin Exp Rheumatol. 2021 Jun 8. Online ahead of print.

MAYO 2021
  • Walker UA, Tilson HH, Hawkins PN, Poll TV, Noviello S, Levy J, Vritzali E, Hoffman HM, Kuemmerle-Deschner JB; CACZ885D2401 Study Investigators.
    Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry. RMD Open. 2021 May;7(2):e001663. doi:10.1136/rmdopen-021-001663

  • Sota J, Rigante D, Cimaz R, Cattalini M, Frassi M, Manna R, Sicignano LL, Verrecchia E, Aragona E, Maggio MC, Lopalco G, Emmi G, Parronchi P, Cauli A, Wiesik-Szewczyk E, Hernández-Rodríguez J, Gaggiano C, Tarsia M, Mourabi M, Ragab G, Vitale A, Fabiani C, Frediani B, Lamacchia V, Renieri A, Luca C; Autoinflammatory Diseases Alliance (AIDA) and the Autoinflammatory Diseases Working Group of the Italian Society of Rheumatology (SIR).
    Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry.
    Rheumatology (Oxford). 2021 May 7:keab419. doi:10.1093/rheumatology/keab419

ABRIL 2021
  • Liu M, Yu Y, Hu S
    A review on applications of abatacept in systemic rheumatic diseases.
    Int Immunopharmacol. 2021 Apr 3;96:107612. doi: 10.1016/j.intimp.2021.107612

  • Nassar-Sheikh Rashid A, Schonenberg-Meinema D, Bergkamp SC, Bakhlakh S, de Vries A, Rispens T, Kuijpers TW, Wolbink G, van den Berg JM
    Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
    Pediatr Rheumatol Online J. 2021 Apr 29;19(1):59.

MARZO 2021
  • Harhay R, Jeelani W, Agbor BTA, Hennon T, Wrotniak BH, Abdul-Aziz R.
    Response to treatment with intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligo articular juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2021 Mar 20;19(1):36. doi: 10.1186/s12969-021-00520-6.

  •  Yue X, Huang B, Hincapie AL, Wigle PR, Qiu T, Li Y, Morgan EM, Guo JJ.
    Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Paediatr Drugs. 2021 Mar;23(2):171-182. doi: 10.1007/s40272-021-00436-4.

  •  Doudouliaki T, Papadopoulou C, Deakin CT.
    Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.
    Curr Rheumatol Rep. 2021 Mar 8;23(4):24. doi: 10.1007/s11926-021-00990-3.

ENERO 2021
  • Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, De Benedetti F; Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2021 Jan 28:keab047. doi: 10.1093/rheumatology/keab047. Epub ahead of print. PMID: 33506875.

  • Melo AT, Campanilho-Marques R, Fonseca JE.
    Golimumab (anti-TNF monoclonal antibody): where we stand today.
    Hum Vaccin Immunother. 2020 Dec 28:1-13

  • Yassin NA, Haroon M, Elhamshary A.
    Methotrexate Hepatotoxicity in Children with Juvenile Idiopathic Arthritis: A Single Center Study.
    Curr Rheumatol Rev. 2020 Dec 11. doi: 10.2174/1573397116666201211123142

  • Brunner HI, Wong R, Nys M, Kou TD, Dominique A, Martini A, Lovell DJ, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
    Paediatr Drugs. 2020 Dec;22(6):653-672

  • Annapureddy N, Nalleballe K, Onteddu SR, Sharma R, Sheng S, Kovvuru S, Siddamreddy S, Mandhadi R.
    Biologics in systemic autoimmune diseases during COVID-19 pandemic.
    Clin Rheumatol. 2020 Dec;39(12):3529-3531

  • Georgin-Lavialle S, Abe E, Larabi A, Savey L, Ducharme-Bénard S, Hentgen V, Grateau G, Alvarez JC.
    Could we measure hair colchicine to assess colchicine observance in familial Mediterranean fever?
    Rheumatology (Oxford). 2020 Dec 21:keaa811

  • Bustamante J, Murias S, Enriquez E, Alcobendas R, Remesal A, Inocencio J.
    Biological therapy in refractory chronic nonbacterial osteomyelitis.
    Joint Bone Spine. 2020 Dec 17:105120

  • Atemnkeng Ntam V, Klein A, Horneff G.
    Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
    Expert Opin Drug Saf. 2020 Nov 18:1-8.
  • Munsel EJ, Bryan PJ, Binstadt BA, Bullock D, Correll CK, Downs EM, Hobday PM, Larson-Nath C, Sudel B, Vehe RK.
    Rapid Infliximab Infusion in the Pediatric Population.
    J Pediatr Pharmacol Ther. 2020;25(8):705-708.
  • Song GG, Lee YH.
    Comparison of the efficacy and safety of biological agents in patients with systemic juvenile idiopathic arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Int J Clin Pharmacol Ther. 2020 Nov 16. doi: 10.5414/CP203791
  • Said MA, Silva LSTE, de Oliveira Rocha AM, Alves GGB, Piotto DGP, Len CA, Terreri MT.
    Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real-life review of a single center cohort.
    Adv Rheumatol. 2020 Nov 5;60(1):53.
  • Horton DB, Xie F, Chen L, Mannion ML, Curtis JR, Strom BL, Beukelman T.
    Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children.
    Am J Epidemiol. 2020 Sep 9:kwaa197. doi: 10.1093/aje/kwaa197. Online ahead of print.

  • Rafael-Vidal C, Pérez N, Altabás I, Garcia S, Pego-Reigosa JM.
    Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases.
    Int J Mol Sci. 2020 Sep 26;21(19):E7100. doi: 10.3390/ijms21197100.

  • Atienza-Mateo B, Remuzgo-Martínez S, Prieto-Peña D, Mora Cuesta VM, Iturbe-Fernández D, Llorca J, Sánchez-Bilbao L, Corrales A, Blanco Rodríguez G, Gómez-Román JJ, Cifrián JM, González-Gay MÁ.
    Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review.
    J Clin Med. 2020 Sep 23;9(10):E3070. doi: 10.3390/jcm9103070.

  • Turmel-Roy J, Bédard MA, Millette M, Simonyan D, Proulx-Gauthier JP, Rousseau-Nepton I.
    Risk of adrenal insufficiency following intra-articular or periarticular corticosteroid injections among children with chronic arthritis.
    J Pediatr Endocrinol Metab. 2020 Aug 26:/j/jpem.ahead-of-print/jpem-2020-0219/jpem-2020-0219.xml. doi: 10.1515/jpem-2020-0219.
  • Koker O, Demirkan FG, Kayaalp G, Cakmak F, Tanatar A, Karadag SG, Sonmez HE, Omeroglu R, Aktay Ayaz N.
    Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19
    Rheumatol Int. 2020 Aug 2;1-11. doi: 10.1007/s00296-020-04663-9.
  • Hashkes PJ.
    50 Years Ago in The Journal of Pediatrics: Revolutionary Changes in the Management of Juvenile Idiopathic Arthritis.
    J Pediatr. 2020 Sep;224:65. doi: 10.1016/j.jpeds.2020.02.044.
JULIO 2020
  • Aragon Cuevas O, Hedrich CM.
    Biosimilars in pediatric rheumatology and their introduction into routine care.
    Clin Immunol. 2020 Jul;216:108447. doi: 10.1016/j.clim.2020.108447. Epub 2020 May 1.

  • Koker O, Sahin S, Adrovic A, Yildiz M, Barut K, Gulle B, Eker Omeroglu R, Kasapcopur O.
    A controversial topic in juvenile idiopathic arthritis: Association between biologic agents and malignancy.
    Int J Rheum Dis. 2020 Jul 20. doi: 10.1111/1756-185X.13906. Epub ahead of print.

  • Marino A, De Souza M, Giani T, Cimaz R.
    Pharmacotherapy for juvenile spondyloarthritis: an overview of the available therapies.
    Expert Opin Pharmacother. 2020 Jul 29:1-8. doi: 10.1080/14656566.2020.1796970. Online ahead of print.

  • Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, Jouzeau JY, Loeuille D, Peyrin-Biroulet L.
    Paradoxical gastrointestinal effects of interleukin-17 blockers.
    Ann Rheum Dis. 2020 Jul 21:annrheumdis-2020-217927. doi: 10.1136/annrheumdis-2020-217927. Epub ahead of print.

JULIO 2020
  • Aragon Cuevas O, Hedrich CM.
    Biosimilars in pediatric rheumatology and their introduction into routine care.
    Clin Immunol. 2020 Jul;216:108447. doi: 10.1016/j.clim.2020.108447. Epub 2020 May 1.

  • Koker O, Sahin S, Adrovic A, Yildiz M, Barut K, Gulle B, Eker Omeroglu R, Kasapcopur O.
    A controversial topic in juvenile idiopathic arthritis: Association between biologic agents and malignancy.
    Int J Rheum Dis. 2020 Jul 20. doi: 10.1111/1756-185X.13906. Epub ahead of print.

  • Marino A, De Souza M, Giani T, Cimaz R.
    Pharmacotherapy for juvenile spondyloarthritis: an overview of the available therapies.
    Expert Opin Pharmacother. 2020 Jul 29:1-8. doi: 10.1080/14656566.2020.1796970. Online ahead of print.

  • Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, Jouzeau JY, Loeuille D, Peyrin-Biroulet L.
    Paradoxical gastrointestinal effects of interleukin-17 blockers.
    Ann Rheum Dis. 2020 Jul 21:annrheumdis-2020-217927. doi: 10.1136/annrheumdis-2020-217927. Epub ahead of print.

JUNIO 2020
  • Ershad M, Vearrier D.
    Ibuprofen Toxicity.
    2020 Jun 29. In: StatPearls [Internet]. Treasure Island (FL). PMID: 30252334

  • Fletcher A, Lassere M, March L, Hill C, Carroll G, Barrett C, Buchbinder R.
    Oral Complementary Medicine Use among People with Inflammatory Arthritis: An Australian Rheumatology Association Database Analysis.
    Int J Rheumatol. 2020 Jun 5;2020:6542965. doi: 10.1155/2020/6542965.

  • Jiang J, Zhao M, Chang C, Wu H, Lu Q.
    Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.
    Clin Rev Allergy Immunol. 2020 Jun 17. doi: 10.1007/s12016-020-08798-2.

  • Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T.
    Translating IL-6 biology into effective treatments.
    Nat Rev Rheumatol. 2020 Jun;16(6):335-345. doi: 10.1038/s41584-020-0419-z

  • Mejbri M, Theodoropoulou K, Hofer M, Cimaz R.
    Interleukin-1 Blockade in Systemic Juvenile Idiopathic Arthritis.
    Paediatr Drugs. 2020 Jun;22(3):251-262. doi: 10.1007/s40272-020-00392-5.

  • Schoemaker CG, Wulffraat NM, Vastert SJ.
    The Patient and Parent Perspective on Methotrexate in Recent Juvenile Idiopathic Arthritis Guidelines: Comment on the Article by Ringold et al.
    Arthritis Rheumatol. 2020 Jun;72(6):1039-1040. doi: 10.1002/art.41234.

MAYO 2020
  • Maccora I, dell'Anna MP, Vannacci A, Simonini G.
    Safety evaluations of adalimumab for childhood chronic rheumatic diseases.
    Expert Opin Drug Saf. 2020 May 14:1-11.
  • Sag E, Bayindir Y, Adiguzel A, Demir S, Bilginer Y, Aytac S, Ozen S.
    Colchicine and Leukopenia: Clinical Implications.
    J Pediatr. 2020 May 13:S0022-3476(20)30444-3.
  • Fiehn C, Ness T, Weseloh C, Specker C, Hadjiski D, Detert J, Krüger K; DGRh Kommission Pharmakotherapie
    Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.
    Z Rheumatol. 2020 Mar 31. doi: 10.1007/s00393-020-00785-4. Online ahead of print.
  • Cuevas OA, Hedrich CM.
    Biosimilars in pediatric rheumatology and their introduction into routine care
    Clin Immunol. 2020 Apr 30:108447. doi: 10.1016/j.clim.2020.108447. Online ahead of print.
  • Cron RQ, Chatham WW.
    The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.
    J Rheumatol. 2020 Apr 25:jrheum.200492. doi: 10.3899/jrheum.200492. Online ahead of print.
  • Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R; Pediatric Rheumatology Group of the Milan Area.
    Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs.
    J Rheumatol. 2020 Apr 25:jrheum.200483. doi: 10.3899/jrheum.200483. Online ahead of print.
MARZO 2020
  • Cimaz R, Maioli G, Calabrese G.
    Current and emerging biologics for the treatment of juvenile idiopathic arthritis.Expert Opin Biol Ther. 2020 Mar 2:1-16. doi: 10.1080/14712598.2020.1733524. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32116038
  • Elewaut D, Braun J, Anderson JK, Arikan D, Chen S, Hojnik M, De Craemer AS, Curtis JR.
    Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases.
    Arthritis Care Res (Hoboken). 2020 Feb 26. doi: 10.1002/acr.24175. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32100944
  • Ho ACH, Wong SN, Leung LCK, Chan WKY, Chong PCY, Tse NKC, Yeung RHM, Kong SY, Lee KP.
    Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement.
    Hong Kong Med J. 2020 Feb;26(1):56-65. doi: 10.12809/hkmj198195.
  • Kahlenberg JM, Billi AC, Eyerich K, Gudjonsson JE.
    Biologics in the treatment of skin and rheumatologic diseases.
    J Allergy Clin Immunol. 2020 Feb 26. pii: S0091-6749(20)30270-0. doi: 10.1016/j.jaci.2020.02.017.
  • Smits RM, Veldhuijzen DS, van Middendorp H, Hissink Muller PCE, Armbrust W, Legger E, Wulffraat NM, Evers AWM.
    Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance.
    Pediatr Rheumatol Online J. 2020 Feb 7;18(1):12. doi: 10.1186/s12969-020-0407-5.
  • Zabotti A, Goletti D, Lubrano E, Cantini F.
    The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis.
    Expert Opin Drug Saf. 2020 Jan;19(1):69-82
  • Tektonidou MG.
    JAK inhibitors: promising for a wider spectrum of autoimmune diseases?
    Lancet. 2019 Dec 7;394(10214):2047-2048
  • Koç R, Sönmez HE, Çakan M, Karadağ ŞG, Tanatar A, Çakmak F, Aktay Ayaz N.
    Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center.
    Rheumatol Int. 2019 Dec 21. doi: 10.1007/s00296-019-04498-z.
  • Noguera-Julian A, Calzada-HernÁndez J, Brinkmann F, Basu Roy R, Bilogortseva O, Buettcher M, Carvalho I, Chechenyeva V, Falcon L, Goetzinger F, Guerrero-Laleona C, Hoffmann P, Jelusic M, Niehues T, Ozere I, Shackley F, Suciliene E, Welch SB, Schölvinck EH, Ritz N, Tebruegge M.
    Tuberculosis disease in children and adolescents on therapy with anti-tumor necrosis factor-alpha agents: a collaborative, multi-centre ptbnet study.
    Clin Infect Dis. 2019 Dec 4. pii: ciz1138. doi: 10.1093/cid/ciz1138
  • Buckley LH, Xiao R, Perman MJ, Grossman AB, Weiss PF.
    Psoriasis Associated with Tumor Necrosis Factor-Alpha Inhibitors in Children with Inflammatory Diseases.
    Arthritis Care Res (Hoboken). 2019 Oct 23. doi: 10.1002/acr.24100. [Epub ahead of print]
  • Park EH, Lee EY, Shin K, Kim HA.
    Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review
    Rheumatol Int. 2019 Oct 9. doi: 10.1007/s00296-019-04456-9. [Epub ahead of print] Review.
  • Renton WD, Leveret H, Guly C, Smee H, Leveret J, Ramanan AV.
    Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
    Pediatr Rheumatol Online J. 2019 Oct 4;17(1):67. doi: 10.1186/s12969-019-0366-x
  • Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P.
    JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
    Autoimmun Rev. 2019 Sep 11:102390. doi: 10.1016/j.autrev.2019.102390. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31520803
  • Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Koné-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric RheumatologyCollaborative Study Group (PRCSG).
    Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
    J Rheumatol. 2019 Sep;46(9):1117-1126. doi: 10.3899/jrheum.180795. Epub 2019 Mar 1.
  • Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW.
    Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
    Arthritis Rheumatol. 2019 Sep 18. doi: 10.1002/art.41121. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31532077
  • Sota J, Rigante D, Ruscitti P, Insalaco A, Sfriso P, de Vita S, Cimaz R, Lopalco G, Emmi G, La Torre F, Fabiani C, Olivieri AN, Cattalini M, Cammelli D, Gallizzi R, Alessio M, Manna R, Viapiana O, Frassi M, Pardeo M, Maier A, Salvarani C, Talarico R, Mosca M, Colafrancesco S, Priori R, Maggio MC, Gaggiano C, Grosso S, De Benedetti F, Vitale A, Giacomelli R, Cantarini L.
    Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease.
    Front Pharmacol. 2019 Aug 23;10:918. doi: 10.3389/fphar.2019.00918. eCollection 2019.
  • Soyer O, Demir S, Bilginer Y, Batu ED, Sonmez EH, Arıcı SZ, Şahiner ÜM, Sekerel BE, Ozen S.
    Severe Hypersensitivity Reactions to Biological Drugs in Children with Rheumatic Diseases.
    Pediatr Allergy Immunol. 2019 Aug 16. doi: 10.1111/pai.13114.
  • Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C.
    Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Pediatr Rheumatol Online J. 2019 Aug 22;17(1):57.
JULIO 2019
  •  Verstegen RHJ, McMillan R, Feldman BM, Ito S, Laxer RM
    Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review.
    Rheumatology (Oxford). 2019 Jul 23. pii: kez285. doi: 10.1093/rheumatology/kez285. [Epub ahead of print]
  • Shenoi S, Nanda K, Schulert GS, Bohnsack JF, Cooper AM, Edghill B, Gillispie-Taylor MC, Goldberg B, Halyabar O, Mason TG, Ronis T, Schneider R, Vehe RK, Onel K; CARRA Systemic Juvenile Idiopathic Arthritis Workgroup.
    Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
    Pediatr Rheumatol Online J. 2019 Jul 22;17(1):48.

  • Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V et al.
    Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis
    Arthritis Rheumatol. 2019 Jul 16. doi: 10.1002/art.41043. [Epub ahead of print]
  • Hand RM, Salman S, Newall N, Vine J, Page-Sharp M, Bowen AC, et al.
    A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies.
    J Antimicrob Chemother. 2019 Jul 1;74(7):1984-1991.
JUNIO 2019
  • Groth D, Perez M, Treat JR, Castelo-Soccio L, Nativ S, Weiss PF, Lapidus S, Perman MJ.
    Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
    Pediatr Dermatol. 2019 Jun 25. doi: 10.1111/pde.13859. [Epub ahead of print]
  • Diener C, Horneff G.
    Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review.
    Expert Opin Drug Saf. 2019 Jun 26:1-14. doi: 10.1080/14740338.2019.1632288
ABRIL 2019
  • Pan S, Yu H, Surti A, Cheng I, Marks SD, Brogan PA, Eleftheriou D, Standing JF.
    Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases.
    Br J Clin Pharmacol. 2019 Apr 26. doi: 10.1111/bcp.13970. [Epub ahead of print]
MARZO 2019
  • Doeleman MJH, van Maarseveen EM, Swart JF.
    Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.
    Rheumatology (Oxford). 2019 Feb 26. pii: kez030. doi: 10.1093/rheumatology/kez030. [Epub ahead of print]
  • Leu JH, Adedokun OJ, GarganoC, Hsia EC, Xu Z, Shankar G
    Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

    Rheumatology (Oxford) 2019 Mar; 58(3):441–446
  • Wilkinson MGL, Rosser EC.
    B Cells as a Therapeutic Target in Paediatric Rheumatic Disease.
    Front Immunol. 2019 Feb 14;10:214. doi: 10.3389/fimmu.2019.00214. eCollection 2019.
  • Doeleman MJH, van Maarseveen EM, Swart JF.
    Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.
    Rheumatology (Oxford). 2019 Feb 26. pii: kez030. doi:
    10.1093/rheumatology/kez030. [Epub ahead of print]
  • Aydin V, Akici A, Isli F, Aksoy M, Aydin M, Gursoz H.
    Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.
    J Clin Pharm Ther. 2019 Feb 14. doi: 10.1111/jcpt.12814. [Epub ahead of print]
  • Nijhuis L, Peeters JGC, Vastert SJ, van Loosdregt J.
    Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
    Front Immunol. 2019 Feb 7;10:151. doi: 10.3389/fimmu.2019.00151. eCollection 2019.
ENERO 2019
  • Nagy A, Mátrai P, Hegyi P, Alizadeh H, Bajor J, Czopf L, Gyöngyi Z, Kiss Z, Márta K, Simon M, Szilágyi ÁL, Veres G, Mosdósi B.
    The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis.
    Pediatr Rheumatol Online J. 2019 Jan 18;17(1):4. doi: 10.1186/s12969-019-0305-x.
  • Abreu P, Ávila-Pedretti G, Morel Z, Acosta MI, Cabrera-Villalba S, Melgarejo P, Franco M, Delgadillo P, Román L, Elizaur JG, Paredes E, Cordovilla DO, Palleiro D, Albanese M, Mazzoleni J.
    Seguridad y supervivencia de las terapias biológicas: Primer informe del registro paraguayo-uruguayo de acontecimientos adversos con terapias biológicas. Biobadaguay.
    Reumatol Clin. 2018 Dec 27. pii: S1699-258X(18)30189-X. doi: 10.1016/j.reuma.2018.08.009. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/30595458
  • Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, Panaviene V, Bader-Meunier B, Anton J, Nielsen S, De Benedetti F, Kamphuis S, Staņēviča V, Tracahana M, Ailioaie LM, Tsitsami E, Klein A, Minden K21,22, Foeldvari I, Haas JP, Klotsche J, Horne AC, Consolaro A, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry.
    Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Arthritis Res Ther. 2018 Dec 27;20(1):285. doi: 10.1186/s13075-018-1780-z.
  • Jung JY, Kim MY, Suh CH, Kim HA.
    Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review.
    Pediatr Rheumatol Online J. 2018 Dec 14;16(1):79. doi: 10.1186/s12969-018-0296-z.
  • Lyseng-Williamson KA.
    Anakinra in Still's disease: a profile of its use.
    Drugs Ther Perspect. 2018;34(12):543-553. doi: 10.1007/s40267-018-0572-5. Epub 2018 Oct 31.
  • Aygun D, Sahin S, Adrovic A, Barut K, Cokugras H, Camcıoglu Y, Kasapcopur O.
    The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.
    Clin Rheumatol. 2018 Nov 17. doi: 10.1007/s10067-018-4367-9. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/30448935
  • Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G
    Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
    Scand J Rheumatol. 2018 Nov 9:1-10. doi: 10.1080/03009742.2018.1488182. [Epub ahead of print]
  • Aeschlimann FA, Chong SL, Lyons TW, Beinvogl BC, Góez-Mogollón LM, Tan S, Laxer RM.
    Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses
    J Pediatr. 2018 Oct 11. pii: S0022-3476(18)31239-3. doi: 10.1016/j.jpeds.2018.08.065. [Epub ahead of print]
  • Keppeke LF, Molina J, Miotto E Silva VB, Terreri MTSELRA, Keppeke GD, Schoen TH, Len CA.
    Psychological characteristics of caregivers of pediatric patients with chronic rheumatic disease in relation to treatment adherence.
    Pediatr Rheumatol Online J. 2018 Oct 12;16(1):63. doi: 10.1186/s12969-018-0280-7.
  • Hunter H.
    Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?
    Arch Dis Child. 2018 Sep 27. pii: archdischild-2018-315528. doi: 10.1136/archdischild-2018-315528. [Epub ahead of print]
  • Cabrera N, Lega JC, Kassai B, Wouters C, Kondi A, Cannizzaro E, Woerner A, Chausset A, Roethlisberger S, Jeanneret C, Aeschlimann F, Malik S, Duquesne A, Kaiser D, Higel L, Maes A, Berthet G, Hentgen V, Kone-Paut I, Belot A, Hofer M.
    Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database.
    Joint Bone Spine. 2018 Sep 7. pii: S1297-319X(18)30283-5. doi: 10.1016/j.jbspin.2018.08.003. [Epub ahead of print]
  • Nieto-González JC, Monteagudo I
    Estado actual del tratamiento con infiltraciones intraarticulares en la artritis idiopática juvenil
    Reumatol Clin. 2018 Sep 19. pii: S1699-258X(18)30174-8. doi: 10.1016/j.reuma.2018.07.015. [Epub ahead of print]
  • Ruiz-Medrano J, Díaz-Valle D, Cuiña R, Gegúndez JA, Chhablani J, Majumder PD, Gutierrez-Bonet R.
    The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative.
    J Fr Ophtalmol. 2018 Sep 11. pii: S0181-5512(18)30282-1. doi: 10.1016/j.jfo.2018.02.006. [Epub ahead of print] 

  • Chi H, Teng J, Yang C, Su Y.
    Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.
    Immunotherapy. 2018 Sep;10(12):1033-1039.
  • Randell RL, Adams AV, Van Mater H.
    Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases.
    Pediatr Neurol. 2018 Aug 3. pii: S0887-8994(18)30366-7. doi: 10.1016/j.pediatrneurol.2018.07.016. [Epub ahead of print]
  • Nijhof LN, Nap-van der Vlist MM, van de Putte EM, van Royen-Kerkhof A, Nijhof SL.
    Non-pharmacological options for managing chronic musculoskeletal pain in children with pediatric rheumatic disease: a systematic review.
    Rheumatol Int. 2018 Aug 23. doi: 10.1007/s00296-018-4136-8. [Epub ahead of print]
  • Higgins GC.
    Complications of Treatments for Pediatric Rheumatic Diseases.
    Pediatr Clin North Am. 2018 Aug;65(4):827-854. doi: 10.1016/j.pcl.2018.04.008.
JULIO 2018
  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS.
    Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
    J Pediatr. 2018 Jul 25. pii: S0022-3476(18)30755-8. doi: 10.1016/j.jpeds.2018.05.042. [Epub ahead of print]
  • Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J.
    Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.
    Arch Dis Child. 2018 Jul 19. pii: archdischild-2018-315060. doi: 10.1136/archdischild-2018-315060. [Epub ahead of print]
  • Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, Ravelli A, Taddio A, Zulian F, Cimaz R; Rheumatology Italian Study Group
    Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.
    Pediatr Rheumatol Online J. 2018 Jul 11;16(1):46. doi: 10.1186/s12969-018-0255-8.
  • Bharucha KN, Brunner HI, Calvo Penadés I, Nikishina I, Rubio-Pérez N, Oliveira S, Kobusinska K, Schmeling H, Sztajnbok F, Weller-Heinemann F, Zholobova E, Zulian F, Allen R, Chaitow J, Frane J, Wells C, Ruperto N, De Benedetti F; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.
    Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.
    J Rheumatol. 2018 Aug;45(8):1173-1179. doi: 10.3899/jrheum.170326. Epub 2018 Jul 1.
JUNIO 2018
  • Lovell DJ, Dare JA, Francis-Sedlak M, Ball J, LaMoreaux BD, Von Scheven E, Reinhardt A, Jerath R, Alpan O, Gupta R, Goldsmith D, Zeft A, Naddaf H, Gottlieb B, Jung L, Holt RJ.
    A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2018 Jun 26;16(1):41. doi: 10.1186/s12969-018-0260-y
  • Saint-Georges V, Peternel S, Kaštelan M, Brajac I.
    Tumor Necrosis Factor Antagonists in the Treatment of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Syndrome.
    Acta Dermatovenerol Croat. 2018 Jun;26(2):173-178
  • Emmi G, Urban ML, Imazio M, Gattorno M, Maestroni S, Lopalco G, Cantarini L, Prisco D, Brucato A.
    Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
    Curr Cardiol Rep. 2018 Jun 14;20(8):61. doi: 10.1007/s11886-018-1007-6
  • Xu C, Peng H, Li R, Chai W, Li X, Fu J, Liu K, Yu B, Jia C, Chen J.
    Risk factors and clinical characteristics of deep knee infection in patients with intra-articular injections: A matched retrospective cohort analysis.
    Semin Arthritis Rheum. 2018 Jun;47(6):911-916. doi: 10.1016/j.semarthrit.2017.10.013
  • Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R.
    JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    J Clin Invest. 2018 Jun 11. pii: 98814. doi: 10.1172/JCI98814
  • Brucato A, Emmi G, Cantarini L, Di Lenarda A, Gattorno M, Lopalco G, Marcolongo R, Imazio M, Martini A, Prisco D.
    Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism.
    Intern Emerg Med. 2018 Jun;13(4):475-489. doi: 10.1007/s11739-018-1842-x
MAYO 2018
  • Ringold S, Nigrovic PA, Feldman BM, Tomlinson GA, von Scheven E, Wallace CA, Huber AM, Schanberg LE, Li SC, Weiss PF, Fuhlbrigge RC, Morgan EM, Kimura Y.
    The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans: Toward Comparative Effectiveness in the Pediatric Rheumatic Diseases.
    Arthritis Rheumatol. 2018 May;70(5):669-678. doi: 10.1002/art.40395. Epub 2018 Mar 31.
  • Poddighe D, Romano M, Gattinara M, Gerloni V.
    Biologics for the treatment of Juvenile Idiopathic Arthritis.
    Curr Med Chem. 2018 May 21. doi: 10.2174/0929867325666180522085716. [Epub ahead of print]
  • De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.
    Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    N Engl J Med. 2018 May 17;378(20):1908-1919. doi: 10.1056/NEJMoa1706314.
  • Yazılıtaş F, Aydoğ Ö, Özlü SG, Çakıcı EK, Güngör T, Eroğlu FK, Gür G, Bülbül M.
    Canakinumab treatment in children with familial Mediterranean fever: report from a single center
    Rheumatol Int. 2018 May;38(5):879-885. doi: 10.1007/s00296-018-3993-5. Epub 2018 Feb 15.
  • Yildirim T, Yilmaz R, Uzerk Kibar M, Erdem Y.
    Canakinumab treatment in renal transplant recipients with familial Mediterranean fever.
    J Nephrol. 2018 Jun;31(3):453-455. doi: 10.1007/s40620-018-0475-5. Epub 2018 Feb 14.
  • Poddighe D, Romano M, Gattinara M, Gerloni V.
    Biologics for the treatment of Juvenile Idiopathic Arthritis.
    Curr Med Chem. 2018 May 21. doi: 10.2174/0929867325666180522085716. [Epub ahead of print]
  • Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, Manna R, Cimaz R, Priori R, Talarico R, de Marchi G, Frassi M, Gallizzi R, Soriano A, Alessio M, Cammelli D, Maggio MC, Gentileschi S, Marcolongo R, La Torre F, Fabiani C, Colafrancesco S, Ricci F, Galozzi P, Viapiana O, Verrecchia E, Pardeo M, Cerrito L, Cavallaro E, Olivieri AN, Paolazzi G, Vitiello G, Maier A, Silvestri E, Stagnaro C, Valesini G, Mosca M, de Vita S, Tincani A, Lapadula G, Frediani B, De Benedetti F, Iannone F, Punzi L, Salvarani C, Galeazzi M, Angotti R, Messina M, Tosi GM, Rigante D, Cantarini L; “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology).
    Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.
    Clin Rheumatol. 2018 May 17. doi: 10.1007/s10067-018-4119-x. [Epub ahead of print]
ABRIL 2018
  • Opoka-Winiarska V, Żuber Z, Alexeeva E, Chasnyk V, Nikishina I, Dębowska G, Smolewska E.
    Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
    J Rheumatol. 2018 Apr 15. pii: jrheum.171006. doi: 10.3899/jrheum.171006. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/29654485
  • Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.
    Treating juvenile idiopathic arthritis to target: recommendations of an international task force.
    Ann Rheum Dis. 2018 Apr 11. pii: annrheumdis-2018-213030. doi: 10.1136/annrheumdis-2018-213030. [Epub ahead of print]
  • Bielak M, Husmann E, Weyandt N, Haas JP, Hügle B, Horneff G, Neudorf U, Lutz T, Lilienthal E, Kallinich T, Tenbrock K, Berendes R, Niehues T, Wittkowski H, Weißbarth-Riedel E, Heubner G, Oommen P, Klotsche J, Foell D, Lainka E.
    IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
    Pediatr Rheumatol Online J. 2018 Apr 5;16(1):22. doi: 10.1186/s12969-018-0236-y.
  • Chen Y, Zou K, Sun J, Yang Y, Liu G.
    Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
    Pharmacogenomics. 2018 Apr;19(6):529-538. doi: 10.2217/pgs-2017-0208. Epub 2018 Mar 28.
  • M F Silva J, Ladomenou F, Carpenter B, Chandra S, Sedlacek P, Formankova R, Grandage V, Friswell M, Cant AJ, Nademi Z, Slatter MA, Gennery AR, Hambleton S, Flood TJ, Lucchini G, Chiesa R, Rao K, Amrolia PJ, Brogan P, Wedderburn LR, Glanville JM, Hough R, Marsh R, Abinun M, Veys P.
    Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.
    Blood Adv. 2018 Apr 10;2(7):777-786. doi: 10.1182/bloodadvances.2017014449.
  • Ringold S, Nigrovic PA, Feldman BM, Tomlinson GA, von Scheven E, Wallace CA, Huber AM, Schanberg LE, Li SC, Weiss PF, Fuhlbrigge RC, Morgan EM, Kimura Y.
    The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans: Toward Comparative Effectiveness in the Pediatric Rheumatic Diseases.
    Arthritis Rheumatol. 2018 May;70(5):669-678. doi: 10.1002/art.40395. Epub 2018 Mar 31.
MARZO 2018
  • Marino A, Real-Fernández F, Rovero P, Giani T, Pagnini I, Cimaz R, Simonini G.
    Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations.
    Clin Rheumatol. 2018 Mar 5. doi: 10.1007/s10067-018-4057-7. [Epub ahead of print]
  • Chen Y, Zou K, Sun J, Yang Y, Liu G.
    Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
    Pharmacogenomics. 2018 Mar 28. doi: 10.2217/pgs-2017-0208. [Epub ahead of print]
  • Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S.
    Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
    Mod Rheumatol. 2018 Mar 26:1-12.
  • Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E.
    A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.
    Rheumatol Ther. 2018 Mar 3. doi: 10.1007/s40744-018-0102-x. [Epub ahead of print] 
  • Okihiro A, Hasija R, Fung L, Cameron B, Feldman BM, Laxer R, Schneider R, Silverman E, Spiegel L, Yeung RSM, Tse SML.
    Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study.
    Pediatr Rheumatol Online J. 2018 Mar 14;16(1):17.
  • Bhat T, Coughlin CC.
    Mood changes with methotrexate therapy for dermatologic disease.
    Pediatr Dermatol. 2018 Mar;35(2):253-254.
  • Schoemaker CG, van Dijkhuizen EHP, Vastert SJ.
    Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients
    Pediatr Rheumatol Online J. 2018 Feb 15;16(1):13. doi: 10.1186/s12969-018-0229-x.
  • Höfel L, Eppler B, Storf M, Schnöbel-Müller E, Haas JP, Hügle B.
    Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results
    Pediatr Rheumatol Online J. 2018 Feb 13;16(1):11. doi: 10.1186/s12969-018-0228-y.
  • Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, Mannion MM, Saag KG, Curtis JR.
    Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors
    Ann Rheum Dis. 2018 Feb 9. pii: annrheumdis-2017-212613. doi: 10.1136/annrheumdis-2017-212613
  • Klotsche J, Minden K, Niewerth M, Horneff G.
    Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
    Ann Rheum Dis. 2018 Feb 16. pii: annrheumdis-2017-211968. doi: 10.1136/annrheumdis-2017-211968. [Epub ahead of print]
  • Albert D.
    Prescribing for Children with Rheumatic Disease: Perceived Treatment Approaches between Pediatric and Adult Rheumatologists.
    Arthritis Care Res (Hoboken). 2018 Feb 26. doi: 10.1002/acr.23552. [Epub ahead of print]
  • Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.
    Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
    Ann Rheum Dis. 2018 Feb 22. pii: annrheumdis-2017-212608. doi: 10.1136/annrheumdis-2017-212608. [Epub ahead of print]
ENERO 2018
  • Lee WJ, Lee TA, Suda KJ, Calip GS, Briars L, Schumock GT.
    Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2018 Feb 1;57(2):273-282. doi: 10.1093/rheumatology/kex049.

  • Moghadam-Kia S, Aggarwal R, Oddis CV.
    Biologics for idiopathic inflammatory myopathies.
    Curr Opin Rheumatol. 2017 Nov;29(6):645-651
  • Horneff G, Peitz J, Kekow J, Foell D.
    Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis.
    Scand J Rheumatol. 2017 Nov;46(6):500-501
  • Correll CK, Bullock DR, Cafferty RM, Vehe RK.
    Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
    Clin Rheumatol. 2017 Nov 4
  • Langley RG, Kasichayanula S, Trivedi M, Aras GA, Kaliyaperumal A, Yuraszeck T, Gibbs J, Gibbs M, Kricorian G, Paller AS.
    Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
    J Clin Pharmacol. 2017 Nov 6
  • Stoll ML, Grubbs JA, Beukelman T, Mannion ML, Jester TW, Cron RQ, Crain MJ.
    Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study.
    Pediatr Rheumatol Online J. 2017 Nov 9;15(1):79
  • Mittal L, Zhang L, Feng R, Werth VP.
    Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study.
    J Am Acad Dermatol. 2017 Oct 5. pii: S0190-9622(17)32466-0. doi: 10.1016/j.jaad.2017.09.061. [Epub ahead of print]
  • Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D.
    Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.
    Ther Drug Monit. 2017 Aug;39(4):370-378. doi: 10.1097/FTD.0000000000000423.
JULIO 2017
  • Ahmet A, Brienza V, Tran A, Lemieux J, Aglipay M, Barrowman N, Duffy C, Roth J, Jurencak R.
    Frequency and Duration of Adrenal Suppression Following Glucocorticoid Therapy in Children With Rheumatic Diseases.
    Arthritis Care Res (Hoboken). 2017 Aug;69(8):1224-1230. doi: 10.1002/acr.23123. Epub 2017 Jul 10.
JUNIO 2017
  • Zhang Y, Milojevic D.
    Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.
    Paediatr Drugs. 2017 Jun;19(3):193-211.
  • López-Ferrer A, Laiz A, Puig L.
    The safety of ustekinumab for the treatment of psoriatic arthritis.
    Expert Opin Drug Saf. 2017 Jun;16(6):733-742.
  • Falvey S, Shipman L, Ilowite N, Beukelman T.
    Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2017 Jun 19;15(1):52
  • Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J, Gordon P, Christidis D, Galloway S, Hayes E, Jeffries A, Mercer S, Mooney J, van Leuven S, Galloway J; BSR and BHPR Standards, Guidelines and Audit Working Group.
    BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
    Rheumatology (Oxford). 2017 Jun 1;56(6):865-868.
  • Kossi S, Dadoun S, Geri G, Hermet A, Fautrel B, Dougados M, Gossec L.
    Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients.
    Rheumatology (Oxford). 2017 Jun 1;56(6):896-900.
  • Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M.
    Low level of Rituximab in human breast milk in a patient treated during lactation.
    Rheumatology (Oxford). 2017 Jun 1;56(6):1047-1048.
  • Chausset A, Fargeix T, Pereira B, Echaubard S, Duquesne A, Desjonquères M, Freychet C, Belot A, Merlin E.
    MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance.
    Clin Rheumatol. 2017 Jun;36(6):1281-1288
  • Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, Mcalindon T.
    2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
    Arthritis Care Res (Hoboken). 2017 Jun 6 doi: 10.1002/acr.23279. [ [Epub ahead of print]
MAYO 2017
  • Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Velázquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell D, Martini A.
    Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
    Ann Rheum Dis. 2017 May 15. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28507219
  • Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, Mcalindon T.
    2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
    Arthritis Care Res (Hoboken). 2017 Jun 6. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28585410
  • Gentileschi S, Rigante D, Vitale A, Sota J, Frediani B, Galeazzi M, Cantarini L.
    Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.
    Clin Rheumatol. 2017 May 23. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28536823
  • Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, Sakuraba A.
    Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
    J Autoimmun. 2017 May;79:4-16. doi: 10.1016/j.jaut.2017.02.003.
  • Goodman DM.
    Pediatric clinical trials-number needed to recruit.
    J Pediatr. 2017 May;184:1-2. doi: 10.1016/j.jpeds.2017.03.011.
  • Stefanska AM, Distlerová D, Musaus J, Olski TM, Dunder K, Salmonson T, Mentzer D, Müller-Berghaus J, Hemmings R, Veselý R.
    Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.
    Arch Dis Child. 2017 May 29. [Epub ahead of print] Review.
ABRIL 2017
  • Mauro A, Rigante D, Cimaz R.
    Investigational drugs for treatment of juvenile idiopathic arthritis
    Expert Opin Investig Drugs. 2017 Apr;26(4):381-387. doi: 10.1080/13543784.2017.1301929. Epub 2017 Mar 12. Review.
MARZO 2017
  • Scott LJ.
    Sarilumab: First Global Approval.
    Drugs. 2017 Apr;77(6):705-712.
  • Roszkiewicz J, Smolewska E.
    In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?
    Curr Rheumatol Rep. 2017 Apr;19(4):19. doi: 10.1007/s11926-017-0646-8
  • Zhang X, Chen YC, Terao K.
    Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis.
    Expert Rev Clin Pharmacol. 2017 Mar 15:1-12. doi: 10.1080/17512433.2017.1300058. [Epub ahead of print]
  • Lee M, Isaacs J.
    The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis.
    Eur J Rheumatol. 2017 Mar;4(1):68-69. doi: 10.5152/eurjrheum.2016.055.
  • Nakamura H, Sugai T, Kato M, Hatanaka KC, Atsumi T
    Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis.
    Clin Exp Rheumatol. 2017 Jan-Feb;35(1):174. Epub 2017 Jan 5.
ENERO 2017
  • Scheuern A1, Tyrrell PN2, Haas JP1, Hügle B3.
    Countermeasures against methotrexate intolerance in juvenile idiopathic arthritis instituted by parents show no effect.
    Rheumatology (Oxford). 2017 Jan 24. pii: kew507. doi: 10.1093/rheumatology/kew507. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28122960
  • Brachat AH, Grom AA, Wulffraat N, Brunner HI, Quartier P, Brik R, McCann L, Ozdogan H, Rutkowska-Sak L, Schneider R, Gerloni V, Harel L, Terreri M, Houghton K, Joos R, Kingsbury D, Lopez-Benitez JM, Bek S, Schumacher M, Valentin MA, Gram H, Abrams K, Martini A, Lovell DJ, Nirmala NR, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.
    Arthritis Res Ther. 2017 Jan 23;19(1):13. doi: 10.1186/s13075-016-1212-x.
  • Lakhanpal A, Brahn E.
    Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.
    Clin Rheumatol. 2016 Dec;35(12):2869-2875.
  • Windschall D, Horneff G.
    Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Clin Rheumatol. 2016 Dec;35(12):2925-2931.
  • Verazza S, Davì S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, Nicolai R, Marafon DP, De Benedetti F, Gerloni V, Pontikaki I, Rovelli F, Cimaz R, Marino A, Zulian F, Martini G, Pastore S, Sandrin C, Corona F, Torcoletti M, Conti G, Fede C, Barone P, Cattalini M, Cortis E, Breda L, Olivieri AN, Civino A, Podda R, Rigante D, La Torre F, D'Angelo G, Jorini M, Gallizzi R, Maggio MC, Consolini R, De Fanti A, Muratore V, Alpigiani MG, Ruperto N, Martini A, Ravelli A; Italian Pediatric Rheumatology Study Group.
    Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
    Pediatr Rheumatol Online J. 2016 Dec 20;14(1):68.
  • Harrington J, Holmyard D, Silverman E, Sochett E, Grynpas M.
    Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids.
    Pediatr Rheumatol Online J. 2016 Nov 10;14(1):58.
  • McDonagh JE, Shaw KL, Prescott J, Smith FJ, Roberts R, Gray NJ.
    "Sometimes I feel like a pharmacist": identity and medication use among adolescents with juvenile arthritis.
    Pediatr Rheumatol Online J. 2016 Oct 19;14(1):57.
JULIO 2016
    Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children.
    Pediatrics. 2016 Aug;138(2). pii: e20161209. doi: 10.1542/peds.2016-1209. Epub 2016 Jul 18.
  • Orrock JE, Ilowite NT.
    Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
    Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6.
JUNIO 2016
  • Fráňová J, Fingerhutová Š, Kobrová K, Srp R, Němcová D, Hoza J, Uher M, Saifridová M, Linková L, Doležalová P.
    Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
    Pediatr Rheumatol Online J. 2016 Jun 14;14(1):36. doi: 10.1186/s12969-016-0099-z
  • Sterba Y, Ilowite N.
    Biologics in Pediatric Rheumatology: Quo Vadis?
    Curr Rheumatol Rep. 2016 Jul;18(7):45. doi: 10.1007/s11926-016-0593-9
MAYO 2016
ABRIL 2016
MARZO 2016
  • Nguyen TA, Celano NJ, Matiz C.
    Palisaded Neutrophilic Granulomatous Dermatitis in a Child with Juvenile Idiopathic Arthritis on Etanercept.
    Pediatr Dermatol. 2016 Mar;33(2):e156-7. doi: 10.1111/pde.12797. Epub 2016 Feb 10.
  • Taddio A, Cattalini M, Simonini G, Cimaz R.
    Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.
    Expert Rev Clin Immunol. 2016 Feb 19:1-9. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26809126
  • Lopalco G, Rigante D, Giannini M, Galeazzi M, Lapadula G, Iannone F, Cantarini L.
    Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
    Clin Exp Rheumatol. 2016 Feb 26. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26940286
  • Calzada-Hernández J, Anton-López J, Bou-Torrent R, Iglesias-Jiménez E, Ricart-Campos S, Martín de Carpi J; Carmen García de Vicuña Muñoz de la Nava, Torrente-Segarra V, Sánchez-Manubens J, Giménez-Roca C, Rozas-Quesada L, Juncosa-Morros MT, Fortuny C, Noguera-Julian A.
    Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.

    Pediatr Rheumatol Online J. 2015 Dec 3;13(1):54. doi: 10.1186/s12969-015-0054-4.
  • Vaz JL, Fernandes V, Nogueira F, Arnóbio A, Levy RA.
    Infliximab-induced autoantibodies: a multicenter study.
    Clin Rheumatol. 2015 Dec 17.
  • Hügle B, Horneff G.
    The Role of Synthetic Drugs in the Biologic Era: Therapeutic Strategies for Treating Juvenile Idiopathic Arthritis.

    Expert Opin Pharmacother. 2015 Dec 17.
  • Agapitos Patakas, Rui-Ru Ji, William Weir, Sean E. Connolly, Robert A. Benson, Steven G. Nadler, James M Brewer, Iain B McInnes and Paul Garside
    Abatacept inhibits T cell priming by inducing of a unique transcriptional profile that reduces their ability to activate antigen presenting cells
    Arthritis & Rheumatology
    DOI: 10.1002/art.39470
  • Doyt L. Conn
    Is the Availability of Delayed Release Prednisone an Important Clinical Advance?
    Arthritis Care & Research
    DOI: 10.1002/acr.22745
  • Matthew Laurence Stoll, Yoginder Nath Vaid, Saurabh Guleria, Timothy Beukelman, Peter Daniel Waite, and Randy Quentin Cron
    Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis

    J Rheumatol November 2015 42(11):2155-2159; doi:10.3899/jrheum.150308
  • Anna Felis-Giemza and Robert J. Moots
    Measurement of anti-drug antibodies to biologic drugs

    Rheumatology (2015) 54 (11): 1941-1943 doi:10.1093/rheumatology/kev279
  • Tania S. Amin, Sian Shenton, Kathleen Mulligan, Lucy R. Wedderburn, Mark Wood, Vanessa VanRooyen, and Valentina Leone
    Strategies for the prevention and management of methotrexate-related nausea and vomiting in juvenile idiopathic arthritis: results of a UK Paediatric Rheumatology prescriber survey
    Rheumatology (2015) 54 (11): 2108-2109 doi:10.1093/rheumatology/kev259
  • Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC.
    Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study
    Arthritis Res Ther. 2015 Oct 22;17(1):295.
  • Horneff G.
    Biologic-Associated Infections in Pediatric Rheumatology
    Curr Rheumatol Rep. 2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z.
  • Ding HJ, Denniston AK, Rao VK, Gordon C.
    Hydroxychloroquine-related retinal toxicity
    Rheumatology (Oxford). 2015 Oct 1. pii: kev357. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26428520
  • Rondeau JM, Ramage P, Zurini M, Gram H.
    The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.
    MAbs. 2015 Aug 18:0. EPUB ahead of print]
JULIO 2015
  • Horneff G
    Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
    Expert Opin Drug Saf. 2015 Jul;14(7):1111-26. doi: 10.1517/14740338.2015.1042453.
JUNIO 2015
  • Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH.
    Rituximab for IgG4-related disease: a prospective, open-label trial.
    Ann Rheum Dis. 2015 Jun;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605.
  •  Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium.
    Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Ann Rheum Dis. 2015 Jun;74(6):1087-93. doi: 10.1136/annrheumdis-2013-204851.
  •  Scheinberg M.
    Therapy: Facing up to biosimilar agents-the ACR position.
    Nat Rev Rheumatol. 2015 Jun;11(6):322-4. doi: 10.1038/nrrheum.2015.57.
MAYO 2015
    • Hermine I Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane, Olivier Harari, Andrew Kenwright, et al for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
      Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
      Ann Rheum Dis. 2015;74:1110-1117 doi:10.1136/annrheumdis-2014-205351
ABRIL 2015
  • Bulatović Ćalasan M, Vastert SJ, Scholman RC, Verweij F, Klein M, Wulffraat NM, Prakken BJ, van Wijk F.
    Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis
    Rheumatology (Oxford). 2015 Apr 14. pii: kev101. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25877908
MARZO 2015
    • Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, Touitou I, Koné-Paut I; MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on the behalf of CRI (Club Rhumatisme et Inflammation).
      Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
      Orphanet J Rare Dis. 2015 Feb 15;10(1):19. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25758134
    • Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL.
      Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis
      Rheumatology (2015) 54 (4): 736-742. doi:10.1093/rheumatology/keu408
    • Strand V, Burmester GR, Zerbini CAF, Mebus CA, Zwillich SH, Gruben D, Wallenstein GV.
      Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
      Arthritis Care Res (Hoboken) 2015; 67(4):475-483. DOI: 10.1002/acr.22453
    • Séïté JF, Hillion S, Harbonnier T, Pers JO.
      Review: intravenous immunoglobulin and B cells: when the product regulates the producer.
      Arthritis Rheumatol. 2015 Mar;67(3):595-603. doi: 10.1002/art.38910
  • Burnett HF, Ungar WJ, Regier DA, Feldman BM, Miller FA.
    Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
    Value Health. 2014 Dec;17(8):830-7. doi: 10.1016/j.jval.2014.08.2668. Epub 2014 Nov 6.
    Präger TM, Meyer P, Rafayelyan S, Minden K, Jost-Brinkmann PG.
    Effect of methotrexate on the mandibular development of arthritic rabbits.
    Eur J Orthod. 2014 Dec 17. pii: cju070. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25518996
  • Shimizu M, Hamaguchi Y, Ishikawa S, Ueno K, Yachie A.
    Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
    Mod Rheumatol. 2014 Dec 15:1-2.
  • Berard RA, Laxer RM.
    Early aggressive therapy for patients with juvenile idiopathic arthritis: are we there yet?
    J Rheumatol. 2014 Dec;41(12):2343-6.
  • Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, Bohnsack J, Chalom EC, Gewanter HL, Gottlieb B, Hollister R, Hsu J, Hudgins A, Ilowite NT, Klein-Gitelman M, Lindsley C, LopezBenitez JM, Lovell DJ, Mason T, Milojevic D, Moorthy LN, Nanda K, Onel K, Prahalad S, Rabinovich CE, Ray L, Rouster-Stevens K, Ruth N, Shishov M, Spalding S, Syed R, Stoll M, Vehe RK, Weiss JE, White AJ, Wallace CA, Sobel RE.
    A novel method to collect medication adverse events in juvenile arthritis: Results from the Childhood Arthritis and rheumatology research alliance enhanced drug safety surveillance project (EDSSP).
    Arthritis Care Res (Hoboken). 2014 Oct 20. doi: 10.1002/acr.22487. [Epub ahead of print]
  • Windschall D, Müller T, Becker I, Horneff G.
    Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
    Rheumatol Int. 2014 Sep 11. [Epub ahead of print]
  • Schmeling H, Horneff G, Benseler SM, Fritzler MJ.
    Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
    Nat Rev Rheumatol. 2014 Nov;10(11):682-690. doi: 10.1038/nrrheum.2014.140. Epub 2014 Aug 12. Review.
  • Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
    Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.
  • K A van Schie, M H Hart, E R de Groot, S Kruithof, L A Aarden, G J Wolbink, T Rispens
    Concise report: The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
    Ann Rheum Dis Published Online First: 23 October 2014
  • Mannion ML, Xie F, Curtis JR, Beukelman T.
    Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors.
    J Rheumatol. 2014 Aug 1.
JULIO 2014
  • Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR, Eleftheriou D, Brogan PA, Kneen R, Alper G, Anlar B, Wassmer E, Heineman K, Hemingway C, Riney CJ, Kornberg A, Tardieu M, Stocco A, Banwell B, Gorman MP, Benseler SM, Lim M.
    Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
    Neurology. 2014 Jul 8;83(2):142-50
  • Scott LJ.
    Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases.
    Drugs. 2014 Jul 18. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25034360
  • Dale RC1, Brilot F2, Duffy LV2, Twilt M2, Waldman AT2, Narula S2, Muscal E2, Deiva K2, Andersen E2, Eyre MR2, Eleftheriou D2, Brogan PA2, Kneen R2, Alper G2, Anlar B2, Wassmer E2, Heineman K2, Hemingway C2, Riney CJ2, Kornberg A2, Tardieu M2, Stocco A2, Banwell B2, Gorman MP2, Benseler SM2, Lim M2.
    Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
    Neurology. 2014 Jul 8;83(2):142-50. 
  • [No authors listed]Discrepancy Between Clinical and Radiological Responses to Tocilizumab Treatment in Patients with Systemic-onset Juvenile Idiopathic Arthritis.
    J Rheumatol. 2014 Jul;41(7):1567.
  • Windschall D1, Müller T, Becker I, Horneff G.
    Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-relatedarthritis and psoriasis arthritis.
    Clin Rheumatol. 2014 Jul 18.
  • Sobel RE1, Lovell DJ2, Brunner HI2, Weiss JE3, Morris PW4, Gottlieb BS5, Chalom EC6, Jung LK7, Onel KB8, Petiniot L9, Goldsmith DP10, Nanda K11, Shishov M12, Abramsky S1, Young JP13, Giannini EH2.
    Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry.
    Pediatr Rheumatol Online J. 2014 Jul 16;12:29.
  • Shimizu M1, Ueno K2, Ishikawa S2, Tokuhisa Y2, Inoue N2, Yachie A2.
    Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus.
    Rheumatology (Oxford). 2014 Jul 26.
  • Autmizguine J1, Cohen-Wolkowiez M, Ilowite N; for the RAPPORT investigators.
    Rilonacept Pharmacokinetics in Children With Systemic Juvenile Idiopathic Arthritis.
    J Clin Pharmacol. 2014 Jul 30.
MAYO 2014
  • Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK.
    Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years.
    J Rheumatol. 2014 May 15. pii: jrheum.131231. [Epub ahead of print]
  • Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK.
    Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years.
    J Rheumatol. 2014 May 15. pii: jrheum.131231. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24833759
MARZO 2014
  • Santer M, Ring N, Yardley L, Geraghty AW, Wyke S.
    Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers' views.
    BMC Pediatr. 2014 Mar 4;14(1):63. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24593304
  • Tanaka T, Narazaki M, Ogata A, Kishimoto T.
    A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Semin Immunol. 2014 Mar 1. pii: S1044-5323(14)00010-4. doi: 10.1016/j.smim.2014.01.009. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24594001
  • Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H.
    Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.
    Clin Rheumatol. 2014 Feb 2. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24487484
  • Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H.
    The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
    Rheumatology (Oxford). 2014 Feb;53(2):213-22. doi: 10.1093/rheumatology/ket260. Epub 2013 Aug 14.
  • Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G.
    Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.
    J Rheumatol. 2014 Feb;41(2):286-92. doi: 10.3899/jrheum.130658. Epub 2014 Jan 15.
  • Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller AS, Rabinovich CE, Turner D, Zulian F.
    Methotrexate: new uses for an old drug.
    J Pediatr. 2014 Feb;164(2):231-6. doi: 10.1016/j.jpeds.2013.10.029.
  • Frampton JE.
    Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis.
    Paediatr Drugs. 2013 Oct 24. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24155139
  • Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S,Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.
    Using Registries to Identify Adverse Events in Rheumatic Diseases.
    Pediatrics.2013 Oct 21. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24144710
  • Prince FH, Solomon DH.
    Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?
    J Rheumatol. 2013 Oct;40(10):1643-5. doi: 10.3899/jrheum.130875.
  • Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ
    Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales.
    Nat Rev Rheumatol 2013 Sep 3. doi: 10.1038/nrrheum.2013.134. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23999553
MAYO 2013